In this video I discuss the case of a Kazan Law client whose misdiagnosis and subsequent treatment led to the longest mesothelioma survival documented in medical literature. The lesson is that aggressive mesothelioma treatment–surgery–can significantly prolong a person’s life.
Mesothelioma research can be expected to make great strides in the coming years thanks to new exciting work underway now all over the world by young scientific investigators. Five of this promising group just received the Young Investigator Travel Awards at the twelfth biennial meeting of the International Mesothelioma Interest Group (iMig 2014), held in Capetown, South Africa. Our firm is proud to have initiated this important award in 2008 and to continue to sponsor it. On behalf of all of us at Kazan, McClain, Satterley and Greenwood, we would like to offer our congratulations on receiving the Young Investigator Travel Awards to each of these promising young mesothelioma research scientists.
Their achievements are a source of pride and inspiration to all of us involved in mesothelioma who seek new pathways to treat and cure this devastating disease. We hope they realize how many people – those with mesothelioma, their families and those of us who strive to help them medically and legally – appreciate the outstanding work they are doing in this field.
It is always a pleasure to see hard-working forward-thinking young researchers receiving the recognition they deserve. The award reflects the endless hours they have spent in their labs on their mesothelioma research projects.
We look forward to seeing the results of their future work in mesothelioma research and wish them every success.
2014 iMig Young Investigator Award Recipients
Sébastien Anguille, MD is a researcher at the University of Antwerp and Antwerp University Hospital Edegem Belgium. He is one of the authors of a recent paper “Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study” published in the Journal of Clinical Oncology.
Lincun Wu, MD is a research associate with the University Health Network in Toronto, Canada’s Mesothelioma Research Program at the Princess Margaret Cancer Center. There, Dr. Wu is involved in a research project to improve the outcome of mesothelioma by combining chemotherapy with immunotherapy.
Alistair Cook, PhD is a research assistant professor in the School of Medicine and Pharmacology of the University of Western Australia. He is the lead author of a recent study about a potential new way to improve anti-tumor immunity or chemo-immunotherapy efficacy in mesothelioma treatment.
Tanguy Siewert, MD is an assistant professor of medicine at the University of Chicago. He specializes in head, neck and lung cancers. He studies which novel drugs appear most promising, which individual tumors are more likely to respond to these treatments, and how to successfully combine therapies. Dr. Seiwert uses this pre-clinical knowledge to develop new treatments for use in clinical trials, and to ultimately improve patient care.
Kimberly Birnie is earning a PhD at the Lung Institute of the University of Western Australia where she is focused on malignant mesothelioma research. She has been recognized by the Thoracic Society of Australia and New Zealand for her work
I am pleased that our firm was chosen to present three research abstracts at the International Mesothelioma Interest Group (iMig 2014) conference in Cape Town, South Africa. In this video I provide an introduction to the mesothelioma research abstracts and explain how they are presented at the world’s leading conference on mesothelioma.
We are particularly honored that Kazan Law has been chosen to present some of our own research work at this conference. Like the Boston conference in 2012, this year again in Cape Town we are the only law firm in the world whose work has been accepted for presentation.
Doctor’s office forms, hospital test forms, insurance forms. When you have malignant mesothelioma, you get handed lots of clipboards and wind up filling out lots of forms. But there is one form you need to make your sure you fill out. That’s the Physician Orders for Life-Sustaining Treatment known as the POLST.
As a patient with malignant mesothelioma, there are many things in your life that are not in your control. But the POLST helps give you control over one very important thing – your medical care. The POLST also helps you talk with your healthcare team and your loved ones about your choices. It can help prevent you from receiving unwanted or ineffective medical treatment. In this way, the POLST can help spare your family the anguish of not knowing what type of medical procedures to say yes or no to. It makes sure that your wishes are known and honored.
The decisions documented on the POLST form include whether to:
- Attempt cardiopulmonary resuscitation,
- Administer antibiotics and IV fluids,
- Use a ventilator to help with breathing, and
- Provide artificial nutrition by tube
Where can I get a POLST form?
You can request the form from your doctor. The form can also be found at www.caPOLST.org
Is the POLST required by law?
Filling out a POLST form is entirely voluntary, but as of 2009, California law requires that the physician orders in a POLST be followed by health care providers.
Does the POLST form replace the Advance Care Directive?
The POLST form complements an Advance Directive and is not intended to replace that document. You still need an Advance Directive to appoint a legal health care decision-maker.
What happens to my POLST form after it is completed and signed?
The original POLST form should stay with you at all times.
- In a hospital, your POLST will be in your medical record or file.
- At home, place your POLST in a visible location so it can be found easily by emergency medical personnel – usually on a bedside table or on the refrigerator
Mesothelioma research, like all scientific research, does not happen without funds. Although funds for mesothelioma research come from government agencies, universities and hospitals, it is no secret that money from private sources helps get the ball rolling either through funding the grant application process, additional staff positions, purchasing state-of-the-art equipment or helping to support conferences where researchers from all over the world can sit together and really discuss ideas.
That’s why our firm Kazan, McClain, Satterley & Greenwood, A Professional Corporation is proud to be the first law firm to step up and provide substantial financial support for the upcoming 12th biannual International Conference of the International Mesothelioma Interest Group. (iMig)
We are pleased to continue to sponsor the International Mesothelioma Interest Group (iMig 2014) when it convenes in Capetown, South Africa this October, just as we did in Boston in 2012, Kyoto in 2010, Amsterdam in 2008 and Chicago in 2006.
Recently, our support for iMig has grown beyond our role as a sponsor. We were honored that four abstracts from Kazan Law were chosen for poster presentation at iMig’s 2012 Boston conference. Ours were the only papers out of hundreds submitted for presentation that were submitted by attorneys. The information we presented was based on 20 years of experience with asbestos trust funds and 40 years representing asbestos victims. As we focus on the fight for justice for each of our clients, the entirety of our discoveries in this process brings to light implications which we believe are of benefit to the greater good of all mesothelioma cases. It was a privilege to share them. You can see a three-minute video of me explaining their significance here.
iMig is comprised of independent international scientists and clinicians with the mission of working to understand, cure and prevent mesothelioma. The iMig conference is one of the most important meetings where scientific information on finding greater treatment solutions for mesothelioma is presented and discussed. Because we want to see an end to the suffering caused by mesothelioma, our firm has been a generous supporter for years. Our commitment to this cause and this conference is unwavering. We give substantially and we give early.
If you need mesothelioma treatment, the Affordable Care Act may be a way to help you get the care you need now and for the future. Unless of course, the foes of providing health care for all Americans succeed in taking it away.
As of this writing, the Affordable Care Act also known as the ACA, still stands. (It is also known as Obamacare because President Obama has become so identified with his firm support for this measure.) So if you are in need of mesothelioma treatment, the ACA may offer the best way for you to get it.
But you need to get going. According to the federal government’s own website HealthCare.gov you need to enroll by February 15 for coverage starting March 1. Also:
- Open enrollment ends March 31.
- If you haven’t enrolled in coverage by then, you generally can’t buy health coverage until the next open enrollment period for coverage the following year.
- If you don’t have health coverage during 2014, you may have to pay a penalty.
Here are four reasons from the American Cancer Society why the Affordable Care Act can help you with mesothelioma treatment:
1) More cancer survivors can now get care – The program provides immediate access to coverage for people in every state who have been uninsured for six months or more and have cancer or another pre-existing condition.
2) No more “doughnut holes” – The ACA is finally closing the Medicare Part D “doughnut hole”. Immediately after enactment, the law provided a $250 rebate to seniors who hit the coverage gap in Medicare’s prescription drug program. In addition, Medicare beneficiaries will receive discounts on brand-name drugs next year.
3) The well won’t run dry – Health plans will be banned from setting lifetime dollar limits on coverage, ensuring that people with cancer have access to needed care throughout their lifetimes. Annual dollar limits on coverage will be tightly restricted for most plans and will be eliminated altogether in 2014. Patients will no longer have to put off treatments waiting for the new plan year to start.
4) In sickness and in health – Just like marriage, your health plan now takes a vow to you when they take your business. As of this week, health insurers will be barred from dropping people from coverage when they get sick. In other words, you can’t lose your insurance for developing mesothelioma.
Major reforms to health care can seem confusing and even overwhelming. The American Cancer Society has a staff of trained experts available to answer questions 24 hours a day at 800.227.2345. Also check the government’s website for help and sign-up information.
The debate on reforming health care is far from over, but these four real-world benefits alone can have a positive impact on mesothelioma patients, bringing us all one big step closer to access to affordable, health care for all Americans.
Even though I have been a mesothelioma attorney for many years, I never get used to the heartbreak of each and every one of my mesothelioma clients. As I get to know each client and their families, they become more than clients. Each becomes a face I will never forget; a suffering human being who came into my life near the premature end of theirs to seek help and justice. And even though I am a mesothelioma attorney, my biggest wish is that there would be no more mesothelioma clients. No more suffering and pain to individuals and their families from the callously negligent exposure to asbestos from the mesothelioma client’s employer.
That is why I also closely follow medical mesothelioma research and have our firm’s charitable foundation financially support mesothelioma research that someday will help to prolong their lives.
In 2006, I was in Chicago attending a meeting of the International Mesothelioma Interest Group. One of the speakers was a key mesothelioma medical researcher from the prestigious University of Chicago medical school. Hedy Lee Kindler MD is a top international cancer expert and one of the best around for mesothelioma. In fact, she is the director of the Mesothelioma Research Program at the University of Chicago and a recent president of the International Mesothelioma Interest Group.
I spoke with Dr. Kindler who was also treating several of our clients. I was so impressed with the novel approaches she and her team were taking and decided to recommend to our Board of Directors that we financially support their work through the firm’s charitable foundation. And every year, I receive a wonderful summary of the research that contribution is helping to fund.
Dr. Kindler and her colleague Dr. Ravi Salgia now are evaluating a signaling pathway – molecules that kickstart cell activity – which appears to play a pivotal role in cell growth in malignant mesothelioma. Their goal of blocking this pathway could prove to be crucial to developing new mesothelioma therapies.
Other researchers in the program are carrying out studies using over 100 mesothelioma tissue samples and cells from the University of Chicago’s Thoracic Tumor Bank. These studies also will help clarify how specific pathways get activated in mesothelioma and how genetically-engineered drugs can target them.
“The opportunities in our clinical research program to deliver focused targeted therapies give us confidence that we will play a critical role in improving survival and outcomes for mesothelioma patients. Your partnership continues to help us achieve our shared vision,” states my annual thank you letter.
I am proud to be part of that vision.
Because it may take decades for symptoms of malignant mesothelioma to develop to the point that it can be diagnosed, it is highly likely that a person suffering from mesothelioma could be over 65. And if a mesothelioma patient is over 65, it is possible that he or she is on Medicare. But you could be eligible for Medicare benefits if you require mesothelioma treatment even if you are under 65.
Medicare is the federal government’s healthcare program intended primarily for older Americans. It covers qualifying individuals age 65 or older. But it also covers people under age 65 who are disabled and suffering from serious illnesses like mesothelioma.
When a worker who has paid a sufficient amount into the Social Security system becomes unable to hold a job for at least 12 months, he or she is eligible for Social Security disability (SSD) benefits. If you meet the criteria for disability, you could begin receiving Medicare two years after being approved for SSD.
But if you receive a personal injury legal settlement, you may have to use part of it to repay Medicare for your mesothelioma treatment. Medicare refers to their reimbursement right as a “reimbursement claim” but it is basically the same as a healthcare lien. Federal law requires all parties to “consider Medicare’s interests” in third party settlements where Medicare has made what are called “conditional payments” for injury-related care.
The term “conditional payments” describes the injury-related healthcare payments Medicare made for your mesothelioma treatment, although another party caused – and is legally responsible for – your injury. Medicare pays for your care on the condition that the responsible party’s funds will be used to pay the program back for your treatment.
A federal law called The Medicare Modernization Act of 2003 requires you and your attorney to inform Medicare that they made a “conditional payment.” Your attorney should request a conditional payment summary, then analyze, review and resolve Medicare’s claims for reimbursement. At Kazan Law, we work hard for our clients and part of that is making sure that you do not get stuck using your settlement to pay medical bills that have been inflated in anticipation of a settlement claim. When we obtain large settlements for our clients, we also see to it that they get to keep as much of it as possible by carefully examining insurance and Medicare itemized claims and medical bills, and negotiating appropriate deductions for the value of our efforts in collecting the funds so that typically our clients end up paying less than half the claimed amount.
One of the dangers of asbestos-related diseases, such as malignant mesothelioma, is that you may not know you’re sick until you develop symptoms. This process can take between 20 and 50 years, and by the time you notice problems, most treatment options are limited to palliative care.
The long latency periods of these diseases mean that many patients are advanced in age. Scientists think this may be a problem because the cells of the immune system behave differently as people age, and this may not be helpful in cases of cancer.
But what if scientists could somehow reverse the aging process of these immune cells? Researchers from Australia may have succeeded in doing that very thing.
How does the immune system work?
Your immune system is quite a powerful weapon, designed to protect your body from bacteria, fungi and viruses. These cells are also tasked to scavenge and clean up injured or damaged cells, including cancerous cells. Experts say that if the immune system turned against us, we wouldn’t stand a chance.
So how exactly does the immune system work? There are two main types of cells:
- Phagocytes are cells that “eat” potentially harmful matter, such as pathogens and damaged cells. Granulocytes, dendritic cells and macrophages are all considered phagocytes. Macrophages in particular are known for eating larger matter
- Lymphocytes are white blood cells that “learn” to recognize different types of harmful cells so they can attack them more effectively. They can identify viruses, bacteria and cancer cells. B-cells and T-cells are both considered varieties of lymphocytes.
The different parts of the immune system usually work together. For example, macrophages not only eat harmful matter, but they also put the other cells of the immune system on alert in case there’s some type of infection.
Researchers make old cells young
Researchers from Australia’s Curtin University theorize that cancer is particularly prevalent among older individuals because their macrophages become less active, and therefore cannot help the immune system kill off malignant cells. They say this may be especially true of mesothelioma and lung cancer.
This concept also led them to explore what would happen if they could make the macrophages of older individuals act like those of younger subjects. For their experiment, they looked at young and old mice, both groups of which were initially healthy. After the scientists exposed them to mesothelioma cells, they noticed the immune systems of the older mice were more sluggish to respond. However, after the researchers treated them with a certain drug, the macrophages of the older mice became active and helpful again.
Scientist Connie Jackaman had this to say to Science Network in Western Australia:
“Immune dysfunction is not permanent and in fact can be restored to function similarly to a young immune system. The public may be interested to know that as they get older it is not necessarily all downhill. The next step for our research group is to see if we can target macrophages in a live model and induce tumor regression in elderly immune systems.”
In the U.S., more than 7,300 individuals die every year because of malignant mesothelioma or asbestos-induced lung cancer. The long latency periods of asbestos-induced diseases mean that their incidence probably won’t peak for another 10 years or so. This is true for the U.S., the U.K. and Australia.
These trends are what motivate scientists in their search for a cure for asbestos-related diseases, and they’re what motivates us at Kazan Law to keep fighting for our clients.